Arcutis Biotherapeutics (NasdaqGS:ARQT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics Inc's fourth quarter fiscal year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will hear an automated mes ...

Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Event**: FY Conference held on February 25, 2026 Core Business and Product Performance - **Product**: Auvelity for Major Depressive Disorder (MDD) - **Sales Achievement**: Over $500 million in sales in 2025, three years post-launch [2] - **Salesforce Expansion**: Increased from 300 to 600 sales representatives to enhance market penetration, particularly in primary care [4] - **Market Access**: Improved access with 86% of covered lives, including 100% in the government channel [7][8] - **First Line Prescriptions**: 50% of total prescriptions are for first line or first switch patients [8] Market Dynamics and Growth Drivers - **Uptake Drivers**: Increased awareness, trial engagement, and a differentiated product profile leading to positive patient outcomes [9] - **Retention Rates**: Currently tracking in line with typical antidepressant persistence, with over 50% of patients being first line or first switch [11][12] - **Alzheimer's Disease Agitation (ADA) Opportunity**: Anticipation of FDA's PDUFA date on April 30, 2026, for Auvelity's indication in Alzheimer's agitation [15] Clinical Data and Regulatory Insights - **Clinical Trials**: Four controlled trials conducted, with three positive outcomes supporting efficacy and safety [22][23] - **Safety Profile**: No significant safety concerns noted, particularly regarding falls or mortality in the elderly population [24] - **Market Size for ADA**: Approximately 5 million Alzheimer's patients experience agitation, with 20 million scripts written annually, predominantly off-label [20] Go-to-Market Strategy - **Pre-launch Activities**: Non-branded campaigns to raise awareness about Alzheimer's agitation and education for healthcare providers [27] - **Reimbursement Strategy**: Full coverage anticipated for Medicare Part D, which constitutes over 70% of total scripts for Alzheimer's agitation [28] - **Expected GTN Improvement**: Anticipated better gross-to-net (GTN) for ADA scripts compared to MDD due to the nature of Medicare Part D [28] Future Catalysts and Pipeline - **Upcoming Trials**: Ongoing trials for binge eating disorder (BED) and shift work disorder, with top-line results expected in the second half of 2026 [35][36] - **New Product AXS-12**: NDA submission imminent, leveraging existing sales force for potential launch in narcolepsy [39] - **New Asset AXS-17**: Recently in-licensed for epilepsy, complementing the existing CNS pipeline [42] Financial Outlook - **Cash Flow Positivity**: Near-term expectations for cash flow positivity remain unchanged, with recent quarters showing close to cash flow positive results [53][54] - **Sales Projections**: Peak sales for Auvelity projected between $2.5 billion and $6 billion, viewed as achievable based on current market dynamics [34] Conclusion - Axsome Therapeutics is positioned for significant growth with its product Auvelity, particularly in the MDD and Alzheimer's agitation markets. The company is actively expanding its sales force, improving market access, and preparing for upcoming product launches and regulatory approvals. The financial outlook remains positive, with a focus on achieving cash flow positivity and leveraging its robust pipeline for future growth.

免责声明：本文内容与数据由观点根据公开信息整理，不构成投资建议，使用前请核实。 据招股书，天辰生物医药是一家致力于创新药开发的临床阶段生物制药公司，主要专注于针对过敏性及 自身免疫性疾病的生物药物的自主发现与开发。天辰生物医药已构建针对鼻科、皮肤科、呼吸科、血液 科、肾脏科及其他自身免疫性疾病的综合性生物制剂产品管线。 来源：观点地产网 观点网讯：2月25日，天辰生物医药（苏州）股份有限公司向港交所提交上市申请书，独家保荐人为国 金证券（香港）。 ...

上海之江生物科技股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688317 证券简称：之江生物 公告编号：2026-006 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 是否需要提交股东会审议：否 ● 日常关联交易对公司的影响：本次预计的2026年度日常关联交易，是公司正常生产经营需要，以市场 价格为定价依据，遵循平等自愿原则，交易风险可控，不会因该关联交易对关联方形成依赖，不会对公 司的独立性产生影响，不存在损害公司及股东利益的情况。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 上海之江生物科技股份有限公司（以下简称"公司"或"之江生物"）于2026年2月24日召开第五届董事会 第十八次会议，审议通过了《关于2026年度日常关联交易预计的议案》。该议案关联董事邵俊斌先生及 倪卫琴女士对部分关联交易进行了回避表决。出席会议的非关联董事一致同意该议案。 独立董事专门会议审议通过该议案，并形成以下意见：公司对2026年度日常关联交易的预计符合正常的 业务发展需要， ...

Group 1 - The core point of the announcement is that Beijing Kain Technology Co., Ltd. has signed a supplementary agreement regarding the technology transfer contract with Hangzhou Xianweida Biotechnology Co., Ltd. for GLP-1 related drug technology, clarifying future revenue arrangements from this collaboration [1][2] - The original technology transfer contract was signed in May 2019, allowing Kain Technology to receive a share of future floating revenues from the technology results generated by Xianweida [1][2] - The supplementary agreement specifies that Kain Technology will receive a revenue share of 5% for products developed using recombinant expression technology and 2.5% for those using chemical synthesis [3][2] Group 2 - The signing of the supplementary agreement aims to further clarify revenue sharing arrangements based on different production processes for products derived from the original contract [3] - The agreement is expected to have no significant adverse impact on the company's financial status and aligns with its long-term strategic goals [3][2] - The future revenues from the technology transfer contract and supplementary agreement depend on the actual progress of product development, commercialization, and may be influenced by various external factors [4]

前沿生物-U(688221.SH)事件点评 与 GSK 达成 2 个小核酸合作，有望谱写全球发展新篇章 glmszqdatemark 此次与跨国药企 GSK 的合作也是公司全球发展战略的重要契机。一方面彰显了前 沿生物在早期 siRNA 药物发现与开发领域的专业能力，正获得国际市场认可；另 一方面，首付款及后续里程碑付款，可以改善公司现金流，助力公司实现研发资 源的高效配置与战略聚焦。未来，前沿生物可以借助 GSK 在全球临床开发与商业 化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业 化、拓展全球合作奠定坚实基础。 [盈利预测与财务指标 Table_Forcast] | 项目/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 129 | 159 | 220 | 285 | | 增长率（%） | 13.3 | 23.1 | 38.0 | 29.5 | | 归属母公司股东净利润（百万元） | -201 | -186 | -182 | -174 | | 增长率（%） | 38. ...

中证报指出，这种方法无需依赖TCR分子的三维结构信息。只需对筛选出的多个"关键按钮"进行同步改 造，即可增强TCR分子"抓住"癌细胞的能力，从而将T细胞打造成效率超群的"超级守护者"。经改造的T 细胞活化水平更高、杀伤力更强，且能精准辨别敌我、避免误伤健康细胞。目前，该研究在动物模型中 疗效显著，为开发新一代高效、精准的癌症免疫疗法提供了崭新的思路。 据中证报报道，中国科学院分子细胞科学卓越创新中心（生物化学与细胞生物学研究所）研究团队与合 作者开发出"组氨酸扫描法"，能快速定位T细胞表面的T细胞受体（TCR）分子中负责识别癌细胞并启 动清除程序的"关键位点"。对这些位点进行"改造升级"后，TCR分子便化身为高灵敏度的增强版"安检 仪"，显著提升了T细胞清除癌细胞的能力。该策略已在实验中展现出良好的抗癌效果。 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 公司方面，据中证报表示，A股相关概念股有翰宇药业、新开源等。 ...

格隆汇2月25日丨永泰生物-B(06978.HK)公告，公司于2026年2月25日向浦发银行认购结构性存款产品， 投资价值为人民币5000万元。 ...

永泰生物-B(06978)发布公告，公司于2026年2月25日向浦发银行认购结构性存款产品，投资价值为人民 币5000万元。 ...

格隆汇2月25日丨永泰生物-B(06978.HK)公告，公司于2026年2月25日向浦发银行认购结构性存款产品， 投资价值为人民币5000万元。 ...